J01DH03 · Anti-infectives for systemic use

Invanz

Authorised 18 Apr 2002

Indications

Treatment Treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required: intra-abdominal infections; community-acquired pneumonia; acute gynaecological infections; diabetic foot infections of the skin and soft tissue. Prevention Invanz is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Composition

Active substance: ertapenem sodium
International name (INN): ertapenem

Official product information

The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.

Open the EPAR at the EMA

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Medicine: Invanz
Active substance: ertapenem sodium
ATC code: J01DH03
Group

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Anti-infectives for systemic use

Therapeutic area

Community-Acquired Infections, Streptococcal Infections, Staphylococcal Infections, Gram-Negative Bacterial Infections, Surgical Wound Infection, Pneumonia, Bacterial

Marketing authorisation holder

Merck Sharp & Dohme B.V.

Status

Authorised

EU authorisation

18 Apr 2002

EMA product number

EMEA/H/C/000389